BioSpace News Archive

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2023 and highlighted recent progress across its business.

Entrada Therapeutics, Inc. today announced that it has received authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its CTIMP (Clinical Trial of an Investigational Medicinal Product) for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced that it has completed enrollment of its potentially final, confirmatory Phase 3 RESILIENT trial of TNX-102 SL (cyclobenzaprine HCL sublingual tablets) 5.6 mg in fibromyalgia and expects topline data next quarter.

TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announced an agreement for the ex-US commercialization of BRIUMVI® (ublituximab).

Clearside Biomedical, Inc. announced today that its second quarter 2023 financial results will be reported on Monday, August 14, 2023 after the close of the financial markets.

Xtant Medical Holdings, Inc., a global medical technology company focused on surgical solutions for the treatment of spinal disorders, reported financial and operating results for the second quarter ended June 30, 2023.

Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability study for SB5, a biosimilar to Humira ® (adalimumab).

Bio-Path Holdings, Inc. reports interim data from Stage 2 of the Company’s Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia.

Revolution Medicines, Inc. and EQRx, Inc. announced a definitive agreement through which Revolution Medicines plans to acquire EQRx in an all-stock transaction intended to add more than $1 billion in net cash to Revolution Medicines’ balance sheet.

CytoMed Therapeutics Limited announced that the chimeric antigen receptor gamma delta T cell technology, which is exclusively licensed from the Agency for Science, Technology and Research, has been granted a patent by the China National Intellectual Property Administration.